Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4181 High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#4173 The global leadership into malnutrition criteria reveals a high percentage of malnutrition which negatively influences overall survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogues

Introduction: Patients (pts) with GEP-NETs treated with somatostatin analogues (SSA’s) are at risk of malnutrition. This has been reported, using weight loss or body mass index (BMI) only. The Global leadership into malnutrition (GLIM) criteria include weight loss, BMI and sarcopenia. In pts with other types of cancer the presence of malnutrition, has a negative effect on overall survival (OS). In pts with GEP-NETs treated with SSA’s this has not been explored before.

Conference:

Presenting Author: Clement D

Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,

Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,

#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy

Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hota S, Cananea E, Martin W, Clement D, Solis B,

Keywords: Neuroendocrine tumours, carcinoid syndrome, telotristat ethyl,